Pfizer’s Cardiff Oncology CRDF Stock Holding History

Pfizer’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01M	Hold	2,411,575	–	–	1.77%	11
2026 Q1	$3.74M	Hold	2,411,575	–	–	1.57%	11
2025 Q4	$6.78M	Hold	2,411,575	–	–	2.87%	9
2025 Q3	$4.97M	Hold	2,411,575	–	–	1.14%	12
2025 Q2	$7.6M	Hold	2,411,575	–	–	1.32%	8
2025 Q1	$7.57M	Hold	2,411,575	–	–	1.51%	8
2024 Q4	$10.5M	Buy	+2,411,575	New	+$7.54M	0.4%	11

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pfizer's CRDF Position: Q2 2026 in Review

Pfizer held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 2,411,575 shares worth $3.01M. The position accounts for 1.77% of the portfolio, ranked #11.

Pfizer first reported a position in CRDF in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.5M in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Pfizer held 2,411,575 shares of Cardiff Oncology worth $3.01M as of Q2 2026.
Pfizer left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up 1.77% of Pfizer's portfolio in Q2 2026, its #11 holding.
Pfizer first reported a position in Cardiff Oncology in Q4 2024 and has held it in 7 quarters since.
Pfizer's Cardiff Oncology position peaked at $10.5M in Q4 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.